Related references
Note: Only part of the references are listed.Sarcopenia: revised European consensus on definition and diagnosis
Alfonso J. Cruz-Jentoft et al.
AGE AND AGEING (2019)
Body composition changes successfully classify prognosis in patients with mycobacterium avium complex lung disease
Daisuke Akahori et al.
JOURNAL OF INFECTION (2019)
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON
Bruno Crestani et al.
LANCET RESPIRATORY MEDICINE (2019)
Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer
Tateaki Naito et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2019)
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Toby M. Maher et al.
RESPIRATORY RESEARCH (2019)
Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
Ida Pesonen et al.
MULTIDISCIPLINARY RESPIRATORY MEDICINE (2018)
Distinct profile and prognostic impact of body composition changes in idiopathic pulmonary fibrosis and idiopathic pleuroparenchymal fibroelastosis
Yuzo Suzuki et al.
SCIENTIFIC REPORTS (2018)
International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management
E. Dent et al.
JOURNAL OF NUTRITION HEALTH & AGING (2018)
Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone
Yukiko Miura et al.
RESPIRATORY INVESTIGATION (2018)
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
Martin Kolb et al.
THORAX (2017)
Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis
Harold R. Collard et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries
Toby M. Maher et al.
BMC PULMONARY MEDICINE (2017)
Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis
Brett Ley et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer
Tateaki Naito et al.
BMC CANCER (2017)
Therapy for idiopathic pulmonary fibrosis: lessons from pooled data analyses
Lauren K. Troy et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS
Ulrich Costabel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
Carlo Albera et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis
Brett Ley et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Measurement of skeletal muscle radiation attenuation and basis of its biological variation
J. Aubrey et al.
ACTA PHYSIOLOGICA (2014)
Epidemiologic Survey of Japanese Patients with Idiopathic Pulmonary Fibrosis and Investigation of Ethnic Differences
Motoki Natsuizaka et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index
Lisa Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Brett Ley et al.
ANNALS OF INTERNAL MEDICINE (2012)
Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study
Marco Mura et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis
Roland M. du Bois et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble et al.
LANCET (2011)
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Sarcopenia: European consensus on definition and diagnosis
Alfonso J. Cruz-Jentoft et al.
AGE AND AGEING (2010)
Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology
C. Vancheri et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Idiopathic pulmonary fibrosis - A composite physiologic index derived from disease extent observed by computed tomography
AU Wells et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study
BH Goodpaster et al.
JOURNAL OF APPLIED PHYSIOLOGY (2001)
Share Paper
